Life Science News

RSS

Thermo Fisher Scientific receives Ringier Technology Innovation Award

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has received a Ringier Technology Innovation Award for its role in helping Chinese laboratories quickly develop melamine detection capabilities following the discovery of melamine-tainted milk and infant formula in China. The award was presented by Ringier Trade Publishing, which publishes China's leading food industry magazine, Food Manufacturing Journal.

From Thermo Fisher Scientific Inc. 9 Sep 2009

FDA approves new xTAG Cystic Fibrosis 39 Kit v2 from Luminex

Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed solutions, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a new cystic fibrosis (CF) test: the xTAG® Cystic Fibrosis 39 Kit v2.

From Thermo Fisher Scientific Inc. 4 Sep 2009

Covidien to divest three product lines to streamline its portfolio

Covidien (NYSE: COV), a leading global provider of healthcare products, today announced definitive agreements to sell its Sleep Diagnostics and Oxygen Therapy product lines and a proposal to sell its Sleep Therapy product line.

From Chart Industries 4 Sep 2009

Thermo Fisher Scientific to acquire B.R.A.H.M.S. for $470 million

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has signed a definitive agreement to acquire B.R.A.H.M.S. AG for €330 million (approximately $470 million USD). B.R.A.H.M.S. is a leading provider of specialty in-vitro diagnostic tests based on its patented biomarkers for sepsis, cardiovascular and pulmonary diseases, as well as intensive care treatments and prenatal screening.

From Thermo Fisher Scientific Inc. 3 Sep 2009

Illumina delivers its first individual genome sequence to Dr. Hermann Hauser

Illumina, Inc. today announced that it has delivered Hermann Hauser’s genome sequence. Dr. Hauser, Partner, Amadeus Capital Partners Ltd, is the first consumer to purchase Illumina’s individual genome sequencing service working with his physician, Michael Nova, MD, of Pathway Genomics.

From Illumina, Inc. 31 Aug 2009

Affymetrix and Beckman Coulter forge alliance to provide optimized genomic research solutions

Affymetrix, Inc. (Nasdaq: AFFX) and Beckman Coulter, Inc. today announced that they have entered into an agreement to offer researchers co-developed products from the market leaders in microarrays and automated liquid handlers.

From Beckman Coulter Life Sciences - Automation and Genomics 27 Aug 2009

Illumina's new stock repurchase program effective in returning value to shareholders

Illumina, Inc. today announced that its Board of Directors has approved a new stock repurchase program, authorizing the Company to repurchase in the aggregate up to $75 million of its outstanding common stock.

From Illumina, Inc. 25 Aug 2009

Fluxion Biosciences receives a $1.8 million NIH grant for developing microfluidic platform

Fluxion Biosciences, a leading developer of microfluidic systems for functional cell analysis, today announced that it has received a $1.8 million NIH grant for the development of a high-throughput screening platform for anti-microbial drug discovery.

From Fluxion Biosciences 20 Aug 2009

Cytori Therapeutics Q2 2009 financial results

Total revenues were $8.5 million and $10.5 million for the three and six months ended June 30, 2009, respectively, compared to $1.4 million and $2.4 million for the same periods in 2008. As part of Cytori’s Olympus partnership, the Company recognized $7.3 million in development revenue in the second quarter of 2009, due mostly to the completion of enrollment in the cardiovascular disease clinical safety and feasibility studies.

From Evident Corporation - Life Sciences 10 Aug 2009

QIAGEN launches novel product enabling non-invasive prenatal diagnostics and cancer detection

QIAGEN today announced the launch of a novel product for extraction of free circulating fragments of tumor- and fetal-derived nucleic acids as well as viral nucleic acids in human blood. Scientists consider these DNA and RNA fragments to have great potential for the highly sensitive and non-invasive diagnosis of a wide range of diseases, including congenital disorders, malignancies such as colon and lung cancer, and infections.

From QIAGEN Manchester Limited 25 May 2009

The navel shown to be a safe and effective single access route for extracting kidneys

Successful surgery that leaves no scars has become the main objective of the most daring and innovative surgeons.

From Evident Corporation - Life Sciences 12 Mar 2009

Oxford Nanopore announces publication of DNA analysis paper

Oxford Nanopore Technologies ("Oxford Nanopore") today announced the publication of new research in Nature Nanotechnology, demonstrating accurate and continuous identification of DNA bases using nanopores.

From Oxford Nanopore Technologies 23 Feb 2009

New tool for 'right first time' drug manufacture

A technology which provides high quality images of the crystallisation process marks the next step towards a 'right first time' approach to drug manufacture, according to engineers at the University of Leeds.

From Malvern Panalytical 23 Sep 2008

Domainex has core intellectual property rights granted for Europe

Domainex Ltd (Domainex), an innovative biopharmaceutical company, today announced the grant of European Patent No.1442134 for its Combinatorial Domain Hunting (CDH) Technology.

From Domainex 14 Sep 2008

Domainex, has core intellectual property rights granted for Europe

Domainex Ltd (Domainex) today announced the grant of European Patent No.1442134 for its Combinatorial Domain Hunting (CDH) Technology.

From Domainex 10 Sep 2008

Biopharmaceutical spin-out company Domainex, secures funding

Headquartered in London, Domainex is a contract research company specialising in the provision of structural biology and chemistry services to major pharmaceutical and biotechnology firms. The Company is also developing a pipeline of pre-clinical drugs and targets.

From Domainex 23 Apr 2008